Eterna Therapeutics Capital Expenditures Over Time

ERNA Stock  USD 0.29  0.01  2.11%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Eterna Therapeutics Performance and Eterna Therapeutics Correlation.
For information on how to trade Eterna Stock refer to our How to Trade Eterna Stock guide.
  
As of March 4, 2025, Capital Expenditures is expected to decline to about 16.2 K.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eterna Therapeutics. If investors know Eterna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eterna Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(8.54)
Revenue Per Share
0.111
Quarterly Revenue Growth
8.549
Return On Assets
(0.42)
Return On Equity
(11.54)
The market value of Eterna Therapeutics is measured differently than its book value, which is the value of Eterna that is recorded on the company's balance sheet. Investors also form their own opinion of Eterna Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Eterna Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eterna Therapeutics' market value can be influenced by many factors that don't directly affect Eterna Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eterna Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eterna Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eterna Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Capital Expenditures Analysis

Compare Eterna Therapeutics and related stocks such as Arcus Biosciences, Cullinan Oncology LLC, and Annexon Capital Expenditures Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
2010201120122013201420152016201720182019202020212022202320242025
RCUS4.1 M4.1 M4.1 M4.1 M4.1 M4.1 M4.1 M5.5 M3.7 M1.9 M3.1 M26.1 M12 M24 MM10.6 M
CGEM0.00.00.00.00.00.00.0261 K261 K20 K10 K589.2 K1.1 M208 K0.00.0
ANNX567 K567 K567 K567 K567 K567 K567 K567 K17 K267 K464 K1.7 M6.5 M193 K221.9 K210.9 K
GPCR19.019.019.019.019.019.019.019.019.019.019.01.2 K155 K2.2 M1.3 M794.9 K
RLAY1.7 M1.7 M1.7 M1.7 M1.7 M1.7 M1.7 M1.7 M1.7 MM1.9 M3.5 M9.1 M4.1 MM1.9 M
REVB0.00.00.00.00.0582 K582 K804 K861 K526 K132 K132 K0.04.03.63.42
ZURA0.00.00.00.00.00.00.00.00.00.00.00.012 MM9.2 M7.3 M
PHIO59 K59 K15 K78 K95 K57 KK203 KK72 K19 K51 K121 KK4.5 K4.3 K
ZVSA0.00.00.00.00.00.00.00.00.00.00.00.00.01.01.151.21
RNAZ254.8 K254.8 K254.8 K254.8 K254.8 K254.8 K254.8 K254.8 K254.8 K254.8 K254.8 K254.8 K100.9 K35.6 K32 K30.4 K
DAWN92 K92 K92 K92 K92 K92 K92 K92 K92 K92 K92 KM26 K3.2 M2.2 M2.5 M
ABOS40 K40 K40 K40 K40 K40 K40 K40 K40 K40 K40 K40 K161 K21 K24.1 K22.9 K
XFOR170 K170 K170 K170 K170 K170 K73 K42 K34 K174 K1.4 M615 K103 K60 K69 K65.5 K
INZY259 K259 K259 K259 K259 K259 K259 K259 K259 K139 K568 K397 K410 K298 K342.7 K379.7 K
PALI59.2 K480.9 K254.9 K537 K556.3 K243.6 K161.1 K94 K1.7 KKK0.010 KK3.6 K3.4 K
UNCY29 K29 K29 K29 K29 K29 K29 K29 K29 K29 K29 K29 KK12 K10.8 K17.3 K
IMMX7.3 K7.3 K7.3 K7.3 K7.3 K7.3 K7.3 K7.3 K7.3 K7.3 K8028020.052.1 K59.9 K62.9 K
APLS0.00.00.00.019.9 K0.01.7 M1.7 M1.7 M1.7 M5.4 M1.1 M1.5 M773 K403 K382.9 K
ITOS226 K226 K226 K226 K226 K226 K226 K226 K226 K721 K356 K1.2 M938 KM3.4 M3.6 M
TCRX1.2 M1.2 M1.2 M1.2 M1.2 M1.2 M1.2 M1.2 M1.2 M1.2 M4.2 M9.9 M4.2 M3.1 M3.6 MM

Eterna Therapeutics and related stocks such as Arcus Biosciences, Cullinan Oncology LLC, and Annexon Capital Expenditures description

Capital Expenditures are funds used by Eterna Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Eterna Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

My Equities

My Current Equities and Potential Positions

Eterna Therapeutics
ERNA
ClassificationBiotech
LocationNew York; U.S.A
ExchangeNASDAQ Exchange
USD 0.2859
When determining whether Eterna Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Eterna Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Eterna Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Eterna Therapeutics Stock:
Check out Eterna Therapeutics Performance and Eterna Therapeutics Correlation.
For information on how to trade Eterna Stock refer to our How to Trade Eterna Stock guide.
You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Eterna Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Eterna Therapeutics technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Eterna Therapeutics trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...